1-2 of 2
Gary E Mason
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies

Diana Cortes, Brendan Paul Hodkinson, Ashwini Kumar, Sheri Skerget, Gary E Mason, Elizabeth Shearin, Hein Ludlage, Bas D Koster, Colleen Kane, Thomas Renaud, Tobias Kampfenkel, Christoph Heuck, Bhoomika Thakkar, Farheen Zishan, Emma Searle, Hang Quach, Gayathri Ravi, Cyrille Hulin, Wojciech Janowski, Jesus G Berdeja, Sébastien Anguille, Jeffrey V Matous, Cyrille Touzeau, Anne-Sophie Michallet, Ajay K. Nooka, Tara Cochrane, Anita D'Souza, Peter M. Voorhees, Karthik Ramasamy, Aurore Perrot, Andrew Spencer, Gurdeep Parmar, Deeksha Vishwamitra
Journal: Blood
Blood (2024) 144 (Supplement 1): 4653.
https://doi.org/10.1182/blood-2024-200333
Published: 2024
Journal Articles

Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Combination with Daratumumab and Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma: Safety and Efficacy Results from the Phase 1b Monumental-2 Study

Ajay K. Nooka, Tara Cochrane, Anita D'Souza, Jeffrey V Matous, Peter M. Voorhees, Karthik Ramasamy, Aurore Perrot, Andrew Spencer, Cyrille Hulin, Hang Quach, Deeksha Vishwamitra, Ashley Nguyen, Debopriya Ghosh, Elizabeth Shearin, Gary E Mason, Thomas Renaud, Gurdeep Parmar
Journal: Blood
Blood (2024) 144 (Supplement 1): 1975.
https://doi.org/10.1182/blood-2024-199773
Published: 2024